To answer the question whether true remissions in myasthenia gravis occurred, 20 patients were studied with a history of evident, typical myasthenia but in full clinical remission. Two control groups served as a comparison: one of 10 healthy volunteers and the other of 10 patients with generalized, presently active myasthenia. In 17 of the 20 patients in remission single-fibre EMG (SFEMG) abnormalities were found, indicating some subclinical disturbances of neuromuscular transmission (in 3 cases the results were overtly pathological, in 11 cases moderately pathological, and in 3 cases slightly pathological). The abnormalities found in the remission group were much less distinct than those in the group with clinically symptomatic myasthenia. A case illustrates these findings: a man in full remission following thymoma extirpation in whom the SFEMG revealed subclinical disturbances of the neuromuscular transmission. Three weeks later a full clinical relapse occurred. The results obtained suggest that in the majority of patients the remissions are only apparently complete. A pathological jitter in a patient in remission calls for special attention: the patient must be spared any immunological stimuli such as vaccination, injections of sera, infections etc.; no drugs can be given which may increase the neuromuscular block; an immunosuppressive course of treatment should be considered; prognosis should be reconsidered.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/BF00313711 | DOI Listing |
Introduction: Pseudoprogression is a complication observed following CAR-T therapy that can mimic disease progression; however, its incidence is not well defined. This phenomenon is driven by a robust inflammatory response due to the recognition of CAR-T cells targeting the lymphoma. Misinterpreting pseudoprogression as true disease progression could result in unnecessary alterations to the treatment regimen.
View Article and Find Full Text PDFAm J Gastroenterol
January 2025
Inflammatory Bowel Disease Center, Amsterdam University Medical Centers, Amsterdam, Netherlands.
Introduction: Patients with ulcerative colitis (UC) and prior biologic failure may have reduced or delayed efficacy with subsequent advanced therapies. This analysis evaluated the efficacy and safety of ozanimod during the True North (TN) study and its open-label extension (OLE) in biologic-exposed patients with UC.
Methods: TN was a randomized, placebo-controlled 52-week trial (10-week induction, 42-week maintenance period).
Asian J Psychiatr
January 2025
Department of Psychiatry, King George's Medical University, Lucknow, Uttar Pradesh, India. Electronic address:
Background: Transcranial Direct Current Stimulation (tDCS) is an emerging modality with demonstrated efficacy in Major Depressive Disorder (MDD), however, there is paucity of research in adolescent depression. This study attempts to evaluate the safety and efficacy of tDCS in adolescents with MDD as an early augmentation to drug therapy.
Methods: Adolescents with MDD aged 10-18 years were enrolled in the study and allocated to active or sham groups as per randomization.
J Comput Neurosci
December 2024
Department of Applied Mathematics, and Centre for Theoretical Neuroscience, University of Waterloo, 200 University Avenue W, Waterloo, N2L 3G1, ON, Canada.
The use of the term "treatment resistance" (TR) in psychiatry has blossomed over the last two decades, with 20%-60% of all cases now labeled as such. Remaining effective treatment options, however, can be identified for two-thirds of these cases. There is no consensus on definition or criteria for TR within any diagnostic category, and literature review supports a broad range of individual causes of treatment failure (TF), rather than an actual entity of TR.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!